Literature DB >> 22382136

[Atrial fibrillation : new anticoagulants and antiarrhythmic drugs].

E Kaya1, G Frommeyer, G Mönnig, L Eckardt.   

Abstract

Atrial fibrillation is the most common form of arrhythmia and one of the most frequent causes of ischemic stroke. Several new anticoagulants have recently been introduced as alternatives to vitamin-K antagonists for prophylaxis of ischemic stroke and tested in phase-3 studies for efficacy and safety. Identifying patients who will profit in particular from the new anticoagulant therapy is crucial to the clinical application of these drugs. Vernakalant and dronedarone are new antiarrhythmic drugs for rhythm control of atrial fibrillation. However, therapeutic efficacy of the new agents still has to be proven.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22382136     DOI： 10.1007/s00059-012-3589-x

Source DB:  PubMed          Journal:  Herz        ISSN： 0340-9937            Impact factor:   1.443


  23 in total

1.  Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.

Authors:  John W Eikelboom; Lars Wallentin; Stuart J Connolly; Mike Ezekowitz; Jeff S Healey; Jonas Oldgren; Sean Yang; Marco Alings; Scott Kaatz; Stefan H Hohnloser; Hans-Christoph Diener; Maria Grazia Franzosi; Kurt Huber; Paul Reilly; Jeanne Varrone; Salim Yusuf
Journal:  Circulation       Date:  2011-05-16       Impact factor: 29.690

2.  Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.

Authors:  Renato D Lopes; John H Alexander; Sana M Al-Khatib; Jack Ansell; Raphael Diaz; J Donald Easton; Bernard J Gersh; Christopher B Granger; Michael Hanna; John Horowitz; Elaine M Hylek; John J V McMurray; Freek W A Verheugt; Lars Wallentin
Journal:  Am Heart J       Date:  2010-03       Impact factor: 4.749

3.  Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.

Authors: 
Journal:  Am Heart J       Date:  2010-03       Impact factor: 4.749

4.  A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.

Authors:  A John Camm; Alessandro Capucci; Stefan H Hohnloser; Christian Torp-Pedersen; Isabelle C Van Gelder; Brian Mangal; Gregory Beatch
Journal:  J Am Coll Cardiol       Date:  2011-01-18       Impact factor: 24.094

5.  A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.

Authors:  Christian Torp-Pedersen; Dimitar H Raev; Garth Dickinson; Noam N Butterfield; Brian Mangal; Gregory N Beatch
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-08-14

6.  Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.

Authors:  Peter R Kowey; Paul Dorian; L Brent Mitchell; Craig M Pratt; Denis Roy; Peter J Schwartz; Jerzy Sadowski; Dorota Sobczyk; Andrzej Bochenek; Egon Toft
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-12

7.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

8.  Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter.

Authors:  Stuart J Connolly; Harry J G M Crijns; Christian Torp-Pedersen; Martin van Eickels; Christophe Gaudin; Richard L Page; Stefan H Hohnloser
Journal:  Circulation       Date:  2009-09-14       Impact factor: 29.690

9.  Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.

Authors:  Denis Roy; Craig M Pratt; Christian Torp-Pedersen; D George Wyse; Egon Toft; Steen Juul-Moller; Tonny Nielsen; S Lind Rasmussen; Ian G Stiell; Benoit Coutu; John H Ip; Edward L C Pritchett; A John Camm
Journal:  Circulation       Date:  2008-03-10       Impact factor: 29.690

10.  Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated.

Authors:  David J Gladstone; Esther Bui; Jiming Fang; Andreas Laupacis; M Patrice Lindsay; Jack V Tu; Frank L Silver; Moira K Kapral
Journal:  Stroke       Date:  2008-08-28       Impact factor: 7.914
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.